drugset / Trial / NCT06276010
Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO
RandomizedParallel-groupOpen-labelOther
Summary
The purpose of this study is to evaluate the effectiveness and safety of nafamostat mesilate compared with unfractionated heparin for anticoagulation in patients with ECMO after cardiac surgery.
Timeline
- Start
- 2024-07-01
- Primary completion
- 2026-11-01
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Heparin | Other / unclassified | 8 iu/kg | — |
| Subject | Heparin | Other / unclassified | 12 iu/kg | — |
| Subject | Nafamostat | Small molecule | 0.5 mg/kg | — |
Indications
No indication recorded.